• Jump to main navigation
  • Jump to content
U of U Health
  • Billing & Insurance
  • MyChart
Search
  • Find A U of U Health Doctor
  • All U of U Health Services
  • All U of U Health Locations
  • For All U of U Health Patients & Visitors
    • Patient Services
      • Questions About Your Bill?
      • Urgent Care
      • Where to Stay
      • Patients & Family Services
      • Clinical Trials
    • University of Utah Hospital
      • University of Utah Hospital
      • Staying at the Hospital
      • Parking & Valet
      • Looking for Another Location?
    • General Questions
      • 801-581-2668
      • Find an Interpreter
      • About U of U Health
  • Billing & Insurance
  • MyChart
  • Search

Paul F. Bray, MD

  • Clinical Information
  • Academic Information
  • Clinical Trials
  • Patient Resources
  • Videos & News
No Rating Available?
In order to provide our patients and visitors with the most accurate and useful information, we only post physician satisfaction data when a physician has received a minimum of 30 returned surveys. For this provider, we have not yet received the minimum.
0 out of 5 Patient Rating

Languages Spoken: English

Throughout his full academic career, Dr. Bray has continued to care for patients with blood diseases. He currently sees patients in clinic at the University of Utah’s Huntsman Cancer Institute. His clinical interests include: 1) Benign and non-malignant hematology, 2) Disorders of platelet number and function, 3) Bleeding disorders, and 4) Thrombotic disorders.

Dr. Bray’s laboratory performs basic and translational research on 1) the role of platelets in inherited and acquired disorders of hemostasis, thrombosis and cardiovascular disease, 2) genomic and transcriptomic approaches to identification of novel genes and gene variants involved in platelet reactivity and pharmacogenetics, and 3) the role of platelet microRNAs (and other non-coding RNAs) on platelet gene expression and physiology.

He has published more than 160 peer-reviewed papers, book chapters and invited reviews.

Clinical Locations

Sugar House Health Center

801-581-2000

1280 E. Stringham Avenue
Salt Lake City, UT  84106
Map

Specialties

  • Disorders of Platelet Number and Function
  • Hemorrhagic Disorders
  • Coagulation
  • Thrombocythemia
  • Anemia
  • Benign Hematology
  • Hematology/BMT
  • Thrombotic Disorders

Board Certification and Academic Information

Academic Departments Internal Medicine - Professor
Academic Divisions Hematology/BMT
Board Certification American Board of Internal Medicine
American Board of Internal Medicine (Sub: Hematology)
American Board of Internal Medicine (Sub: Medical Oncology)
Federal Licensing Examination
National Board of Medical Examiners

Throughout his full academic career, Dr. Bray has continued to care for patients with blood diseases. He currently sees patients in clinic at the University of Utah’s Huntsman Cancer Institute. His clinical interests include: 1) Benign and non-malignant hematology, 2) Disorders of platelet number and function, 3) Bleeding disorders, and 4) Thrombotic disorders.

Dr. Bray’s laboratory performs basic and translational research on 1) the role of platelets in inherited and acquired disorders of hemostasis, thrombosis and cardiovascular disease, 2) genomic and transcriptomic approaches to identification of novel genes and gene variants involved in platelet reactivity and pharmacogenetics, and 3) the role of platelet microRNAs (and other non-coding RNAs) on platelet gene expression and physiology.

He has published more than 160 peer-reviewed papers, book chapters and invited reviews.

Academic Locations

Huntsman Cancer Hospital

801-585-3229

(801) 585-3432

1950 Circle of Hope
Division of Hematology and Hematologic Malignancies, 4126
Salt Lake City, UT  84112

Research Statement

Dr. Bray has over 30 years of experience in the molecular genetics and cell biology of platelets. In particular, he has a long research interest in arterial thrombosis and has expertise in platelet molecular biology, genetics, RNA expression, microRNAs, genomics and functional characterization of genetic variants, having discovered the first inherited platelet risk factor for myocardial infarction. He has expertise in platelet physiology and designing assays to assess platelet reactivity. He designed and conducted research studies that recruited cohorts to identify genes, SNPs and mRNAs associated with human platelet activation. He was the first to demonstrate viral-vector mediated gene expression in cultured megakaryocytes. His laboratory has used human platelet mRNA expression profiling to discover novel platelet mRNAs and microRNAs associated with platelet aggregation and differentially expressed between different hematopoietic cells. Dr. Bray has extensive experience with candidate SNP and pharmacogenetics association studies in large cohorts, having collaborated and published with the investigators in TIMI, Framingham, John’s Hopkins’ GeneSTAR, the Women’s Health Initiative, and HERS. The PRAX1 study was designed and executed by Dr. Bray. This study resulted in the identification of racial differences in platelet function, and he demonstrated several novel molecular mechanisms to explain these racial differences. He and his collaborators at Baylor College of Medicine generated and maintain a public, user-friendly, interactive web tool (http://www.plateletomics.com) to query human platelet mRNA, microRNA and protein expression, mouse platelet mRNA, and human RNA-demographic and RNA-functional associations, facilitating discovery of mechanisms of platelet-megakaryocyte gene expression.

Dr. Bray has had 30 years of continuous funding from the National Institutes of Health (NIH) and currently is PI on three NIH R01 grants. He has published more than 160 peer-reviewed papers, book chapters and invited reviews.

Board Certification and Academic Information

Academic Departments Internal Medicine - Professor
Academic Divisions Hematology/BMT
Board Certification American Board of Internal Medicine
American Board of Internal Medicine (Sub: Hematology)
American Board of Internal Medicine (Sub: Medical Oncology)
Federal Licensing Examination
National Board of Medical Examiners

Research Interests

  • Molecular Genetic Aspects of Thrombosis
  • Blood Platelet Disorders
  • Coronary Thrombosis
  • Stroke
  • Bleeding Disorders
  • Platelet Aggregation Inhibitors
  • Embolism and Thrombosis

Education History

Postdoctoral Fellowship University of California, San Francisco
Hematology Research
Postdoctoral Fellow, 1986
Fellowship University of California, San Francisco
Hematology/Oncology
Fellow, 1985
Residency Baylor College of Medicine
Internal Medicine
Resident, 1980
Internship Baylor College of Medicine
Internal Medicine
Intern, 1978
Professional Medical University of Utah School of Medicine
Medicine
M.D., 1977
Undergraduate University of San Francisco
Computer Science
B.S., 1972

Selected Publications - Journal Articles

Journal Article

  1. Montenont E, Bhatlekar S, Jacob S, Kosaka Y, Manne BK, Lee O, Parra-Izquierdo I, Tugolukova E, Tolley ND, Rondina MT, Bray PF, Rowley JW (2020). CRISPR-edited megakaryocytes for rapid screening of platelet gene functions. Blood Adv, 5(9), 2362-2374.
  2. Abou-Ismail MY, Rodgers GM, Bray PF, Lim MY (2021). Acquired von Willebrand syndrome in monoclonal gammopathy - A scoping review on hemostatic management. Res Pract Thromb Haemost, 5(2), 356-365.
  3. Bhatlekar S, Manne BK, Basak I, Edelstein LC, Tugolukova E, Stoller ML, Cody MJ, Morley SC, Nagalla S, Weyrich AS, Rowley JW, OConnell RM, Rondina MT, Campbell RA, Bray PF (2020). miR-125a-5p regulates megakaryocyte proplatelet formation via the actin-bundling protein L-plastin. Blood, 136(15), 1760-1772.
  4. Botero JP, Lee K, Branchford BR, Bray PF, Freson K, Lambert MP, Luo M, Mohan S, Ross JE, Bergmeier W, Di Paola J, ClinGen Platelet Disorder Variant Curation Expert Panel (2020). Glanzmann thrombasthenia: genetic basis and clinical correlates. Haematologica, 105(4), 888-894.
  5. Rondina MT, Voora D, Simon LM, Schwertz H, Harper JF, Lee O, Bhatlekar SC, Li Q, Eustes AS, Montenont E, Campbell RA, Tolley ND, Kosaka Y, Weyrich AS, Bray PF, Rowley JW (2019). Longitudinal RNA-Seq Analysis of the Repeatability of Gene Expression and Splicing in Human Platelets Identifies a Platelet SELP Splice QTL. Circ Res, 126(4), 501-516.
  6. Bhatlekar S, Basak I, Edelstein LC, Campbell RA, Lindsey CR, Italiano JE Jr, Weyrich AS, Rowley JW, Rondina MT, Sola-Visner M, Bray PF (2019). Anti-apoptotic BCL2L2 increases megakaryocyte proplatelet formation in cultures of human cord blood. Haematologica, 104(10), 2075-2083.
  7. Megy K, Downes K, Simeoni I, Bury L, Morales J, Mapeta R, Bellissimo DB, Bray PF, Goodeve AC, Gresele P, Lambert M, Reitsma P, Ouwehand WH, Freson K, Subcommittee on Genomics in Thrombosis and Hemostasis (2019). Curated disease-causing genes for bleeding, thrombotic, and platelet disorders: Communication from the SSC of the ISTH. J Thromb Haemost, 17(8), 1253-1260.
  8. Campbell RA, Schwertz H, Hottz ED, Rowley JW, Manne BK, Washington AV, Hunter-Mellado R, Tolley ND, Christensen M, Eustes AS, Montenont E, Bhatlekar S, Ventrone CH, Kirkpatrick BD, Pierce KK, Whitehead SS, Diehl SA, Bray PF, Zimmerman GA, Kosaka Y, Bozza PT, Bozza FA, Weyrich AS, Rondina MT (2019). Human megakaryocytes possess intrinsic antiviral immunity through regulated induction of IFITM3. Blood, 133(19), 2013-2026.
  9. Basak I, Bhatlekar S, Manne BK, Stoller M, Hugo S, Kong X, Ma L, Rondina MT, Weyrich AS, Edelstein LC, Bray PF (2019). miR-15a-5p regulates expression of multiple proteins in the megakaryocyte GPVI signaling pathway. J Thromb Haemost, 17(3), 511-524.
  10. Whitley MJ, Henke DM, Ghazi A, Nieman M, Stoller M, Simon LM, Chen E, Vesci J, Holinstat M, McKenzie SE, Shaw CA, Edelstein LC, Bray PF (2018). The protease-activated receptor 4 Ala120Thr variant alters platelet responsiveness to low-dose thrombin and protease-activated receptor 4 desensitization, and is blocked by non-competitive P2Y12 inhibition. J Thromb Haemost, 16(12), 2501-2514.
  11. Di Paola J, Bray PF (2018). One over PAR or one under PAR: vive la différence. Blood, 132(19), 2007-2008.
  12. Simeoni I, Stephens JC, Hu F, Deevi SV, Megy K, Bariana TK, Lentaigne C, Schulman S, Sivapalaratnam S, Vries MJ, Westbury SK, Greene D, Papadia S, Alessi MC, Attwood AP, Ballmaier M, Baynam G, Bermejo E, Bertoli M, Bray PF, Bury L, Cattaneo M, Collins P, Daugherty LC, Favier R, French DL, Furie B, Gattens M, Germeshausen M, Ghevaert C, Goodeve AC, Guerrero JA, Hampshire DJ, Hart DP, Heemskerk JW, Henskens YM, Hill M, Hogg N, Jolley JD, Kahr WH, Kelly AM, Kerr R, Kostadima M, Kunishima S, Lambert MP, Liesner R, Lpez JA, Mapeta RP, Mathias M, Millar CM, Nathwani A, Neerman-Arbez M, Nurden AT, Nurden P, Othman M, Peerlinck K, Perry DJ, Poudel P, Reitsma P, Rondina MT, Smethurst PA, Stevenson W, Szkotak A, Tuna S, van Geet C, Whitehorn D, Wilcox DA, Zhang B, Revel-Vilk S, Gresele P, Bellissimo DB, Penkett CJ, Laffan MA, Mumford AD, Rendon A, Gomez K, Freson K, Ouwehand WH, Turro E (2016). A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders. Blood, 127(23), 2791-803.
  13. Nagalla S, Bray PF (2016). Personalized medicine in thrombosis: back to the future. Blood, 127(22), 2665-71.
  14. Zhou Y, Abraham S, Andre P, Edelstein LC, Shaw CA, Dangelmaier CA, Tsygankov AY, Kunapuli SP, Bray PF, McKenzie SE (2015). Anti-miR-148a regulates platelet FcgammaRIIA signaling and decreases thrombosis in vivo in mice. Blood, 126(26), 2871-81.
  15. Holinstat M, Bray PF (2015). Emerging innovative therapeutic approaches to protease receptor antagonism [doi: 10.1002/cpt.282.] [Epub ahead of print]. Clin Pharmacol Ther.
  16. Qayyum R, Becker LC, Becker DM, Faraday N, Yanek LR, Leal SM, Shaw C, Mathias R, Suktitipat B, Bray PF (2015). Genome-wide association study of platelet aggregation in African Americans. BMC Genet, 16, 58.
  17. Buitrago L, Rendon A, Liang Y, Simeoni I, Negri A, Filizola M, Ouwehand WH, Coller BS (2015). alphaIIbbeta3 variants defined by next-generation sequencing: predicting variants likely to cause Glanzmann thrombasthenia. Proc Natl Acad Sci U S A, 112(15), E1898-907.
  18. Londin E, Loher P, Telonis AG, Quann K, Clark P, Jing Y, Hatzimichael E, Kirino Y, Honda S, Lally M, Ramratnam B, Comstock CE, Knudsen KE, Gomella L, Spaeth GL, Hark L, Katz LJ, Witkiewicz A, Rostami A, Jimenez SA, Hollingsworth MA, Yeh JJ, Shaw CA, McKenzie SE, Bray P, Nelson PT, Zupo S, Van Roosbroeck K, Keating MJ, Calin GA, Yeo C, Jimbo M, Cozzitorto J, Brody JR, Delgrosso K, Mattick JS, Fortina P, Rigoutsos I (2015). Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs. Proc Natl Acad Sci U S A, 112(10), E1106-15.
  19. Tourdot BE, Conaway S, Niisuke K, Edelstein LC, Bray PF, Holinstat M (2014). Mechanism of race-dependent platelet activation through the protease-activated receptor-4 and Gq signaling axis. Arterioscler Thromb Vasc Biol, 34(12), 2644-50.
  20. Rincon F, Friedman DP, Bell R, Mayer SA, Bray PF (2014). Targeted temperature management after intracerebral hemorrhage (TTM-ICH): methodology of a prospective randomized clinical trial. Int J Stroke, 9(5), 646-51.
  21. Simon LM, Edelstein LC, Nagalla S, Woodley AB, Chen ES, Kong X, Ma L, Fortina P, Kunapuli S, Holinstat M, McKenzie SE, Dong JF, Shaw CA, Bray PF (2014). Human platelet microRNA-mRNA networks associated with age and gender revealed by integrated plateletomics. Blood, 123(16), e37-45.
  22. Dangelmaier C, Manne BK, Liverani E, Jin J, Bray P, Kunapuli SP (2014). PDK1 selectively phosphorylates Thr(308) on Akt and contributes to human platelet functional responses. Thromb Haemost, 111(3), 508-17.
  23. Londin ER, Hatzimichael E, Loher P, Edelstein L, Shaw C, Delgrosso K, Fortina P, Bray PF, McKenzie SE, Rigoutsos I (2014). The human platelet: strong transcriptome correlations among individuals associate weakly with the platelet proteome. Biol Direct, 9, 3.
  24. Teruel-Montoya R, Kong X, Abraham S, Ma L, Kunapuli SP, Holinstat M, Shaw CA, McKenzie SE, Edelstein LC, Bray PF (2014). MicroRNA expression differences in human hematopoietic cell lineages enable regulated transgene expression. PLoS One, 9(7), e102259.
  25. Edelstein LC, Simon LM, Lindsay CR, Kong X, Montoya RT, Tourdot BE, Chen ES, Ma L, Coughlin S, Nieman M, Holinstat M, Shaw CA, Bray PF (2014). Racial variation in the human platelet PAR4 thrombin receptor alters platelet function. Blood, 124, 3450-8.
  26. Edelstein LC, Simon LM, Montoya RT, Holinstat M, Chen ES, Bergeron A, Kong X, Nagalla S, Mohandas N, Cohen DE, Dong JF, Shaw C, Bray PF (2013). Racial differences in human platelet PAR4 reactivity reflect expression of PCTP and miR-376c. Nat Med, 19(12), 1609-16.
  27. Bray PF (2013). Dengue platelets meet Sir Arthur Conan Doyle. Blood, 122(20), 3400-1.
  28. Bray PF, McKenzie SE, Edelstein LC, Nagalla S, Delgrosso K, Ertel A, Kupper J, Jing Y, Londin E, Loher P, Chen HW, Fortina P, Rigoutsos I (2013). The complex transcriptional landscape of the anucleate human platelet. BMC Genomics, 14, 1.
  29. Garcia AE, Rico MC, Liverani E, DeLa Cadena RA, Bray PF, Kunapuli SP (2013). Erosive arthritis and hepatic granuloma formation induced by peptidoglycan polysaccharide in rats is aggravated by prasugrel treatment. PLoS One, 8(7), e69093.
  30. Londin ER, Hatzimichael E, Loher1 P, Edelstein L, Shaw C, Delgrosso K, Fortina P, Bray PF, McKenzie SE, Rigoutsos I (2013). Towards a reference human platelet transcriptome: evaluation of inter-individual correlations and of its relationship with a platelet proteome. Blood, 122, 2297.
  31. Edelstein LC, Luna EJ, Gibson IB, Bray M, Jin Y, Kondkar A, Nagalla S, Hadjout-Rabi N, Smith TC, Covarrubias D, Jones SN, Ahmad F, Stolla M, Kong X, Fang Z, Bergmeier W, Shaw C, Leal SM, Bray PF (2012). Human genome-wide association and mouse knockout approaches identify platelet supervillin as an inhibitor of thrombus formation under shear stress. Circulation, 125(22), 2762-71.
  32. Samama MM, Contant G, Spiro TE, Perzborn E, Guinet C, Gourmelin Y, Le Flem L, Rohde G, Martinoli JL (2012). Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost, 107(2), 379-87.
  33. Stolla M, Pelisek J, von Bruhl ML, Schafer A, Barocke V, Heider P, Lorenz M, Tirniceriu A, Steinhart A, Bauersachs J, Bray PF, Massberg S, Schulz C (2012). Fractalkine is expressed in early and advanced atherosclerotic lesions and supports monocyte recruitment via CX3CR1. PLoS One, 7(8), e43572.
  34. Faraday N, Yanek LR, Yang XP, Mathias R, Herrera-Galeano JE, Suktitipat B, Qayyum R, Johnson AD, Chen MH, Tofler GH, Ruczinski I, Friedman AD, Gylfason A, Thorsteinsdottir U, Bray PF, ODonnell CJ, Becker DM, Becker LC (2011). Identification of a specific intronic PEAR1 gene variant associated with greater platelet aggregability and protein expression. Blood, 118(12), 3367-75.
  35. Hong W, Kondkar AA, Nagalla S, Bergmeier W, Jin Y, Herman JH, Bray PF (2011). Transfection of human platelets with short interfering RNA. Clin Transl Sci, 4(3), 180-2.
  36. Nagalla S, Shaw C, Kong X, Kondkar AA, Edelstein LC, Ma L, Chen J, McKnight GS, Lopez JA, Yang L, Jin Y, Bray MS, Leal SM, Dong JF, Bray PF (2011). Platelet microRNA-mRNA coexpression profiles correlate with platelet reactivity. Blood, 117(19), 5189-97.
  37. Smith WR, Ballas SK, McCarthy WF, Bauserman RL, Swerdlow PS, Steinberg MH, Waclawiw MA (2011). The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Med, 12(5), 697-705.
  38. Rossouw J, Bray P, Liu J, Kooperberg C, Hsia J, Lewis C, Cushman M, Bonds D, Hendrix S, Papanicolaou G, Howard T, Herrington D (2011). Estrogen receptor polymorphisms and the vascular effects of hormone therapy. Arterioscler Thromb Vasc Biol, 31(2), 464-9.
  39. Snoep JD, Gaussem P, Eikenboom JC, Emmerich J, Zwaginga JJ, Holmes CE, Vos HL, de Groot PG, Herrington DM, Bray PF, Rosendaal FR, van der Bom JG (2010). The minor allele of GP6 T13254C is associated with decreased platelet activation and a reduced risk of recurrent cardiovascular events and mortality: results from the SMILE-Platelets project. J Thromb Haemost, 8(11), 2377-84.
  40. Feldman AM, Force TL, Whellan DJ, Bray PF, Cheung JY, Koch WJ (2010). Advancing the research mission in an academic department: the creation of a center for translational medicine. Clin Transl Sci, 3(4), 178-81.
  41. Kondkar AA, Bray MS, Leal SM, Nagalla S, Liu DJ, Jin Y, Dong JF, Ren Q, Whiteheart SW, Shaw C, Bray PF (2010). VAMP8/endobrevin is overexpressed in hyperreactive human platelets: suggested role for platelet microRNA. J Thromb Haemost, 8(2), 369-78.
  42. Bray PF (2009). Platelet genomics beats the catch-22. Blood, 114(7), 1286-7.
  43. McTiernan A, Wactawski-Wende J, Wu L, Rodabough RJ, Watts NB, Tylavsky F, Freeman R, Hendrix S, Jackson R (2009). Low-fat, increased fruit, vegetable, and grain dietary pattern, fractures, and bone mineral density: the Women's Health Initiative Dietary Modification Trial. Am J Clin Nutr, 89(6), 1864-76.
  44. Nambi V, Kimball KT, Bray PF, Bergeron AL, Johnson SL, Morrisett JD, Chen C, Lin PH, Lumsden AB, Ballantyne CM, Dong JF (2009). Differences in responses of platelets to fluid shear stress in patients with peripheral artery disease (PAD) and coronary artery disease (CAD). Platelets, 20(3), 199-205.
  45. Bergmeier W, Oh-Hora M, McCarl CA, Roden RC, Bray PF, Feske S (2009). R93W mutation in Orai1 causes impaired calcium influx in platelets. Blood, 113(3), 675-8.
  46. Rossouw JE, Cushman M, Greenland P, Lloyd-Jones DM, Bray P, Kooperberg C, Pettinger M, Robinson J, Hendrix S, Hsia J (2008). Inflammatory, lipid, thrombotic, and genetic markers of coronary heart disease risk in the women's health initiative trials of hormone therapy. Arch Intern Med, 168(20), 2245-53.
  47. Ball C, Vijayan KV, Nguyen T, Anthony K, Bray PF, Essex DW, Dong JF (2008). Glutathione regulates integrin alpha(IIb)beta(3)-mediated cell adhesion under flow conditions. Thromb Haemost, 100(5), 857-63.
  48. Ritenbaugh C, Stanford JL, Wu L, Shikany JM, Schoen RE, Stefanick ML, Taylor V, Garland C, Frank G, Lane D, Mason E, McNeeley SG, Ascensao J, Chlebowski RT (2008). Conjugated equine estrogens and colorectal cancer incidence and survival: the Women's Health Initiative randomized clinical trial. Cancer Epidemiol Biomarkers Prev, 17(10), 2609-18.
  49. Brunner RL, Cochrane B, Jackson RD, Larson J, Lewis C, Limacher M, Rosal M, Shumaker S, Wallace R (2008). Calcium, vitamin D supplementation, and physical function in the Women's Health Initiative. J Am Diet Assoc, 108(9), 1472-9.
  50. Herrera-Galeano JE, Becker DM, Wilson AF, Yanek LR, Bray P, Vaidya D, Faraday N, Becker LC (2008). A novel variant in the platelet endothelial aggregation receptor-1 gene is associated with increased platelet aggregability. Arterioscler Thromb Vasc Biol, 28(8), 1484-90.
  51. Yee DL, Dinu BR, Sun CW, Edwards RM, Justino H, Teruya J, Bray PF, Bomgaars L (2008). Low prevalence and assay discordance of "aspirin resistance" in children. Pediatr Blood Cancer, 51(1), 86-92.
  52. Bray PF, Larson JC, Lacroix AZ, Manson J, Limacher MC, Rossouw JE, Lasser NL, Lawson WE, Stefanick ML, Langer RD, Margolis KL (2008). Usefulness of baseline lipids and C-reactive protein in women receiving menopausal hormone therapy as predictors of treatment-related coronary events. Am J Cardiol, 101(11), 1599-1605.
  53. Payne KE, Bray PF, Grant PJ, Carter AM (2008). Beta3 integrin haplotype influences gene regulation and plasma von Willebrand factor activity. Atherosclerosis, 198(2), 280-6.
  54. Geng H, Zhang H, Zhang W, Nieswandt B, Bray PF, Leng X (2008). Transdermal 17-beta estradiol replacement therapy reduces megakaryocyte GPVI expression. Thromb Res, 123(1), 93-9.
  55. Bray PF, Mathias RA, Faraday N, Yanek LR, Fallin MD, Herrera-Galeano JE, Wilson AF, Becker LC, Becker DM (2007). Heritability of platelet function in families with premature coronary artery disease. J Thromb Haemost, 5(8), 1617-23.
  56. Faraday N, Yanek LR, Mathias R, Herrera-Galeano JE, Vaidya D, Moy TF, Fallin MD, Wilson AF, Bray PF, Becker LC, Becker DM (2007). Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1. Circulation, 115(19), 2490-6.
  57. Bray PF, Howard TD, Vittinghoff E, Sane DC, Herrington DM (2007). Effect of genetic variations in platelet glycoproteins Ibalpha and VI on the risk for coronary heart disease events in postmenopausal women taking hormone therapy. Blood, 109(5), 1862-9.
  58. Lev EI, Patel RT, Guthikonda S, Lopez D, Bray PF, Kleiman NS (2007). Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel. Thromb Res, 119(3), 355-60.
  59. Faraday N, Becker DM, Yanek LR, Herrera-Galeano JE, Segal JB, Moy TF, Bray PF, Becker LC (2006). Relation between atherosclerosis risk factors and aspirin resistance in a primary prevention population. Am J Cardiol, 98(6), 774-9.
  60. Yee DL, Bergeron AL, Sun CW, Dong JF, Bray PF (2006). Platelet hyperreactivity generalizes to multiple forms of stimulation. J Thromb Haemost, 4(9), 2043-50.
  61. Hendrix SL, Wassertheil-Smoller S, Johnson KC, Howard BV, Kooperberg C, Rossouw JE, Trevisan M, Aragaki A, Baird AE, Bray PF, Buring JE, Criqui MH, Herrington D, Lynch JK, Rapp SR, Torner J (2006). Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation, 113(20), 2425-34.
  62. Curb JD, Prentice RL, Bray PF, Langer RD, Van Horn L, Barnabei VM, Bloch MJ, Cyr MG, Gass M, Lepine L, Rodabough RJ, Sidney S, Uwaifo GI, Rosendaal FR (2006). Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med, 166(7), 772-80.
  63. Becker DM, Segal J, Vaidya D, Yanek LR, Herrera-Galeano JE, Bray PF, Moy TF, Becker LC, Faraday N (2006). Sex differences in platelet reactivity and response to low-dose aspirin therapy. JAMA, 295(12), 1420-7.
  64. Cooke GE, Liu-Stratton Y, Ferketich AK, Moeschberger ML, Frid DJ, Magorien RD, Bray PF, Binkley PF, Goldschmidt-Clermont PJ (2006). Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination. J Am Coll Cardiol, 47(3), 541-6.
  65. Lev EI, Patel RT, Maresh KJ, Guthikonda S, Granada J, DeLao T, Bray PF, Kleiman NS (2006). Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol, 47(1), 27-33.
  66. Bray PF (2006). Platelet reactivity and genetics down on the pharm. Trans Am Clin Climatol Assoc, 117, 103-11; discussion 111-2.
  67. Yee DL, Sun CW, Bergeron AL, Dong JF, Bray PF (2005). Aggregometry detects platelet hyperreactivity in healthy individuals. Blood, 106(8), 2723-9.
  68. Leng XH, Zhang W, Nieswandt B, Bray PF (2005). Effects of estrogen replacement therapies on mouse platelet function and glycoprotein VI levels. Circ Res, 97(5), 415-7.
  69. Vijayan KV, Liu Y, Sun W, Ito M, Bray PF (2005). The Pro33 isoform of integrin beta3 enhances outside-in signaling in human platelets by regulating the activation of serine/threonine phosphatases. J Biol Chem, 280(23), 21756-62.
  70. Margolis KL, Manson JE, Greenland P, Rodabough RJ, Bray PF, Safford M, Grimm RH Jr, Howard BV, Assaf AR, Prentice R (2005). Leukocyte count as a predictor of cardiovascular events and mortality in postmenopausal women: the Women's Health Initiative Observational Study. Arch Intern Med, 165(5), 500-8.
  71. Leng X-H, Bray PF (2005). Hormone therapy and platelet function. Drug Discov Today, 2, 85-91.
  72. Faraday N, Martinez EA, Scharpf RB, Kasch-Semenza L, Dorman T, Pronovost PJ, Perler B, Gerstenblith G, Bray PF, Fleisher LA (2004). Platelet gene polymorphisms and cardiac risk assessment in vascular surgical patients. Anesthesiology, 101(6), 1291-7.
  73. Vijayan KV, Liu Y, Li TT, Bray PF (2004). Protein phosphatase 1 associates with the integrin alphaIIb subunit and regulates signaling. J Biol Chem, 279(32), 33039-42.
  74. Li TT, Larrucea S, Souza S, Leal SM, Lopez JA, Rubin EM, Nieswandt B, Bray PF (2004). Genetic variation responsible for mouse strain differences in integrin alpha 2 expression is associated with altered platelet responses to collagen. Blood, 103(9), 3396-402.
  75. Leng XH, Hong SY, Larrucea S, Zhang W, Li TT, Lopez JA, Bray PF (2004). Platelets of female mice are intrinsically more sensitive to agonists than are platelets of males. Arterioscler Thromb Vasc Biol, 24(2), 376-81.
  76. Yee D, Bray PF (2004). Platelet hyperreactivity: risk factors and the effects of hormones. 4, 72-8.
  77. Zhang JN, Bergeron AL, Yu Q, Sun C, McBride L, Bray PF, Dong JF (2003). Duration of exposure to high fluid shear stress is critical in shear-induced platelet activation-aggregation. Thromb Haemost, 90(4), 672-8.
  78. Kurrelmeyer K, Becker L, Becker D, Yanek L, Goldschmidt-Clermont P, Bray PF (2003). Platelet hyperreactivity in women from families with premature atherosclerosis. J Am Med Womens Assoc (1972), 58(4), 272-7.
  79. Vijayan KV, Huang TC, Liu Y, Bernardo A, Dong JF, Goldschmidt-Clermont PJ, Alevriadou BR, Bray PF (2003). Shear stress augments the enhanced adhesive phenotype of cells expressing the Pro33 isoform of integrin beta3. FEBS Lett, 540(1-3), 41-6.
  80. Vijayan KV, Liu Y, Dong JF, Bray PF (2003). Enhanced activation of mitogen-activated protein kinase and myosin light chain kinase by the Pro33 polymorphism of integrin beta 3. J Biol Chem, 278(6), 3860-7.
  81. Chen J, Dong JF, Sun C, Bergeron A, McBride L, Pillai M, Barnard MR, Salmon J, Michelson AD, Bray PF (2003). Platelet FcgammaRIIA His131Arg polymorphism and platelet function: antibodies to platelet-bound fibrinogen induce platelet activation. J Thromb Haemost, 1(2), 355-62.
  82. Sajid M, Vijayan KV, Souza S, Bray PF (2002). PlA polymorphism of integrin beta 3 differentially modulates cellular migration on extracellular matrix proteins. Arterioscler Thromb Vasc Biol, 22(12), 1984-9.
  83. Wheeler GL, Braden GA, Bray PF, Marciniak SJ, Mascelli MA, Sane DC (2002). Reduced inhibition by abciximab in platelets with the PlA2 polymorphism. Am Heart J, 143(1), 76-82.
  84. Bray PF, Cannon CP, Goldschmidt-Clermont P, Moye LA, Pfeffer MA, Sacks FM, Braunwald E (2001). The platelet Pl(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction. Am J Cardiol, 88(4), 347-52.
  85. Segal JB, Kasper EK, Rohde C, Bray PF, Baldwin WM 3rd, Resar JR, Hruban RH, Kickler TS (2001). Coagulation markers predicting cardiac transplant rejection. Transplantation, 72(2), 233-7.
  86. Woods D, Cherwinski H, Venetsanakos E, Bhat A, Gysin S, Humbert M, Bray PF, Saylor VL, McMahon M (2001). Induction of beta3-integrin gene expression by sustained activation of the Ras-regulated Raf-MEK-extracellular signal-regulated kinase signaling pathway. Mol Cell Biol, 21(9), 3192-205.
  87. Nealen ML, Vijayan KV, Bolton E, Bray PF (2001). Human platelets contain a glycosylated estrogen receptor beta. Circ Res, 88(4), 438-42.
  88. Boudoulas KD, Cooke GE, Roos CM, Bray PF, Goldschmidt-Clermont PJ (2001). The PlA polymorphism of glycoprotein IIIa functions as a modifier for the effect of estrogen on platelet aggregation. Arch Pathol Lab Med, 125(1), 112-5.
  89. Bray PF, Goldschmidt-Clermont P, Furman MI, Michelson AD, Barnard MR, Mascelli MA, Hendrix C, Coleman L, Hamlington J, Kickler T, Christie DJ, Kundu S (2001). Platelet GPIIIa PlA polymorphisms display different sensitivity to agonists. Circulation, 103, E33-4.
  90. McCarty OJ, Mousa SA, Bray PF, Konstantopoulos K (2000). Immobilized platelets support human colon carcinoma cell tethering, rolling, and firm adhesion under dynamic flow conditions. Blood, 96(5), 1789-97.
  91. Wilcox DA, Olsen JC, Ishizawa L, Bray PF, French DL, Steeber DA, Bell WR, Griffith M, White GC 2nd (2000). Megakaryocyte-targeted synthesis of the integrin beta(3)-subunit results in the phenotypic correction of Glanzmann thrombasthenia. Blood, 95(12), 3645-51.
  92. Khetawat G, Faraday N, Nealen ML, Vijayan KV, Bolton E, Noga SJ, Bray PF (2000). Human megakaryocytes and platelets contain the estrogen receptor beta and androgen receptor (AR): testosterone regulates AR expression. Blood, 95(7), 2289-96.
  93. Michelson AD, Furman MI, Goldschmidt-Clermont P, Mascelli MA, Hendrix C, Coleman L, Hamlington J, Barnard MR, Kickler T, Christie DJ, Kundu S, Bray PF (2000). Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists. Circulation, 101(9), 1013-8.
  94. Vijayan KV, Goldschmidt-Clermont PJ, Roos C, Bray PF (2000). The Pl(A2) polymorphism of integrin beta(3) enhances outside-in signaling and adhesive functions. J Clin Invest, 105(6), 793-802.
  95. Faraday N, Rade JJ, Johns DC, Khetawat G, Noga SJ, DiPersio JF, Jin Y, Nichol JL, Haug JS, Bray PF (1999). Ex vivo cultured megakaryocytes express functional glycoprotein IIb-IIIa receptors and are capable of adenovirus-mediated transgene expression. Blood, 94(12), 4084-92.
  96. Goldschmidt-Clermont PJ, Coleman LD, Pham YM, Cooke GE, Shear WS, Weiss EJ, Kral BG, Moy TF, Yook RM, Blumenthal RS, Becker DM, Becker LC, Bray PF (1999). Higher prevalence of GPIIIa PlA2 polymorphism in siblings of patients with premature coronary heart disease. Arch Pathol Lab Med, 123(12), 1223-9.
  97. Pabla R, Weyrich AS, Dixon DA, Bray PF, McIntyre TM, Prescott SM, Zimmerman GA (1999). Integrin-dependent control of translation: engagement of integrin alphaIIbbeta3 regulates synthesis of proteins in activated human platelets. J Cell Biol, 144(1), 175-84.
  98. Irani K, Pham Y, Coleman LD, Roos C, Cooke GE, Miodovnik A, Karim N, Wilhide CC, Bray PF, Goldschmidt-Clermont PJ (1998). Priming of platelet alphaIIbbeta3 by oxidants is associated with tyrosine phosphorylation of beta3. Arterioscler Thromb Vasc Biol, 18(11), 1698-706.
  99. Jin Y, Wilhide CC, Dang C, Li L, Li SX, Villa-Garcia M, Bray PF (1998). Human integrin beta3 gene expression: evidence for a megakaryocytic cell-specific cis-acting element. Blood, 92(8), 2777-90.
  100. Wagner KR, Giles WH, Johnson CJ, Ou CY, Bray PF, Goldschmidt-Clermont PJ, Croft JB, Brown VK, Stern BJ, Feeser BR, Buchholz DW, Earley CJ, Macko RF, McCarter RJ, Sloan MA, Stolley PD, Wityk RJ, Wozniak MA, Price TR, Kittner SJ (1998). Platelet glycoprotein receptor IIIa polymorphism P1A2 and ischemic stroke risk: the Stroke Prevention in Young Women Study. Stroke, 29(3), 581-5.
  101. Wilhide CC, Jin Y, Guo Q, Li L, Li SX, Rubin E, Bray PF (1997). The human integrin beta3 gene is 63 kb and contains a 5'-UTR sequence regulating expression. Blood, 90(10), 3951-61.
  102. Faraday N, Goldschmidt-Clermont PJ, Bray PF (1997). Gender differences in platelet GPIIb-IIIa activation. Thromb Haemost, 77(4), 748-54.
  103. Goldschmidt-Clermont PJ, Schulman SP, Bray PF, Chandra NC, Grigoryev D, Dise KR, Sagar M, Fox RJ, Coleman LD, Richardson C, Dorsey FC, du Mee C, Kitt MM, Ouyang P, Baughman KL, Gerstenblith G (1996). Refining the treatment of women with unstable angina--a randomized, double-blind, comparative safety and efficacy evaluation of Integrelin versus aspirin in the management of unstable angina. Clin Cardiol, 19(11), 869-74.
  104. Schulman SP, Goldschmidt-Clermont PJ, Topol EJ, Califf RM, Navetta FI, Willerson JT, Chandra NC, Guerci AD, Ferguson JJ, Harrington RA, Lincoff AM, Yakubov SJ, Bray PF, Bahr RD, Wolfe CL, Yock PG, Anderson HV, Nygaard TW, Mason SJ, Effron MB, Fatterpacker A, Raskin S, Smith J, Brashears L, Gottdiener P, du Mee C, Kitt MM, Gerstenblith G (1996). Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial. Circulation, 94(9), 2083-9.
  105. Jin Y, Dietz HC, Montgomery RA, Bell WR, McIntosh I, Coller B, Bray PF (1996). Glanzmann thrombasthenia. Cooperation between sequence variants in cis during splice site selection. J Clin Invest, 98(8), 1745-54.
  106. Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, Weiss JL, Gerstenblith G, Goldschmidt-Clermont PJ (1996). A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med, 334(17), 1090-4.
  107. King KE, Kao KJ, Bray PF, Casella JF, Blakemore K, Callan NA, Kennedy SD, Kickler TS (1996). The role of HLA antibodies in neonatal thrombocytopenia: a prospective study. Tissue Antigens, 47(3), 206-11.
  108. Weiss EJ, Goldschmidt-Clermont PJ, Grigoryev D, Jin Y, Kickler TS, Bray PF (1995). A monoclonal antibody (SZ21) specific for platelet GPIIIa distinguishes P1A1 from P1A2. Tissue Antigens, 46(5), 374-81.
  109. Kim HO, Jin Y, Kickler TS, Blakemore K, Kwon OH, Bray PF (1995). Gene frequencies of the five major human platelet antigens in African American, white, and Korean populations. Transfusion, 35(10), 863-7.
  110. Sohn RH, Chen J, Koblan KS, Bray PF, Goldschmidt-Clermont PJ (1995). Localization of a binding site for phosphatidylinositol 4,5-bisphosphate on human profilin. J Biol Chem, 270(36), 21114-20.
  111. Addo JB, Bray PF, Grigoryev D, Faraday N, Goldschmidt-Clermont PJ (1995). Surface recruitment but not activation of integrin alpha IIb beta 3 (GPIIb-IIIa) requires a functional actin cytoskeleton. Arterioscler Thromb Vasc Biol, 15(9), 1466-73.
  112. Wilhide CC, Van Dang C, Dipersio J, Kenedy AA, Bray PF (1995). Overexpression of cyclin D1 in the Dami megakaryocytic cell line causes growth arrest. Blood, 86(1), 294-304.
  113. Bray PF, Jin Y, Kickler T (1994). Rapid genotyping of the five major platelet alloantigens by reverse dot-blot hybridization. Blood, 84(12), 4361-7.
  114. Furman MI, Grigoryev D, Bray PF, Dise KR, Goldschmidt-Clermont PJ (1994). Platelet tyrosine kinases and fibrinogen receptor activation. Circ Res, 75(1), 172-80.
  115. Faraday N, Goldschmidt-Clermont P, Dise K, Bray PF (1994). Quantitation of soluble fibrinogen binding to platelets by fluorescence-activated flow cytometry. J Lab Clin Med, 123(5), 728-40.
  116. Villa-Garcia M, Li L, Riely G, Bray PF (1994). Isolation and characterization of a TATA-less promoter for the human beta 3 integrin gene. Blood, 83(3), 668-76.
  117. Bertagnolli ME, Locke SJ, Hensler ME, Bray PF, Beckerle MC (1993). Talin distribution and phosphorylation in thrombin-activated platelets. J Cell Sci, 106 ( Pt 4), 1189-99.
  118. Jin Y, Dietz HC, Nurden A, Bray PF (1993). Single-strand conformation polymorphism analysis is a rapid and effective method for the identification of mutations and polymorphisms in the gene for glycoprotein IIIa. Blood, 82(8), 2281-8.
  119. Li L, Bray PF (1993). Homologous recombination among three intragene Alu sequences causes an inversion-deletion resulting in the hereditary bleeding disorder Glanzmann thrombasthenia. Am J Hum Genet, 53(1), 140-9.
  120. Bray PF, Luka J, Bray PF, Culp KW, Schlight JP (1992). Antibodies against Epstein-Barr nuclear antigen (EBNA) in multiple sclerosis CSF, and two pentapeptide sequence identities between EBNA and myelin basic protein. Neurology, 42(9), 1798-804.
  121. Bray PF, Culp KW, McFarlin DE, Panitch HS, Torkelson RD, Schlight JP (1992). Demyelinating disease after neurologically complicated primary Epstein-Barr virus infection. Neurology, 42(2), 278-82.
  122. Call GK, Bray PF, Smoker WR, Buys SS, Hayes JK (1990). Carotid thrombosis following neck irradiation. Int J Radiat Oncol Biol Phys, 18(3), 635-40.
  123. Bray PF, Shuman MA (1990). Identification of an abnormal gene for the GPIIIa subunit of the platelet fibrinogen receptor resulting in Glanzmann thrombasthenia. Blood, 75, 881-88.
  124. Bray PF, Leung S-I, Shuman MA (1990). Human platelets and megakaryocytes contain alternately spliced glycoprotein IIb mRNAs. J Biol Chem, 265, 9587-90.
  125. Luo XY, Bray PF, Magenis RE (1989). Precise localization of the gene for platelet membrane glycoprotein IIb to 17q21.32 using structural rearrangements of chromosome 17. Cytogenet Cell Genet, 51, 1036.
  126. Rosa JP, Bray PF, Gayet O, Johnston GI, Cook RG, Jackson KW, Shuman MA, McEver RP (1988). Cloning of glycoprotein IIIa cDNA from human erythroleukemia cells and localization of the gene to chromosome 17. Blood, 72(2), 593-600.
  127. Bray PF, Barsh G, Rosa J-P, Luo XY, Magenis E, Shuman MA (1988). Physical linkage of the genes for platelet membrane glycoprotein IIb and IIIa. Proc Natl Acad Sci U S A, 85, 8683-87.
  128. Edwards CQ, Carrol M, Bray P, Cartwright GE (1977). Hereditary hemochromatosis: Diagnosis in siblings and children. N Engl J Med, 297, 7-13.

Review

  1. Edelstein LC, McKenzie SE, Shaw C, Holinstat MA, Kunapuli SP, Bray PF (2013). MicroRNAs in platelet production and activation. [Review]. J Thromb Haemost, 11 Suppl 1, 340-50.
  2. Wang TY, Angiolillo DJ, Cushman M, Sabatine MS, Bray PF, Smyth SS, Dauerman HL, French PA, Becker RC (2012). Platelet biology and response to antiplatelet therapy in women: implications for the development and use of antiplatelet pharmacotherapies for cardiovascular disease. [Review]. J Am Coll Cardiol, 59(10), 891-900.
  3. Edelstein LC, Bray PF (2012). Small RNAs as potential platelet therapeutics. [Review]. Handb Exp Pharmacol, (210), 435-45.
  4. Edelstein LC, Bray PF (2011). MicroRNAs in platelet production and activation. [Review]. Blood, 117(20), 5289-96.
  5. Williams MS, Weiss EJ, Sabatine MS, Simon DI, Bahou WF, Becker LC, Parise LV, Dauerman HL, French PA, Smyth SS, Becker RC (2010). Genetic regulation of platelet receptor expression and function: application in clinical practice and drug development. [Review]. Arterioscler Thromb Vasc Biol, 30(12), 2372-84.
  6. Kleiman NS, Freedman JE, Tracy PB, Furie BC, Bray PF, Rao SV, Phillips DR, Storey RF, Rusconi CP, French PA, Steinhubl SR, Becker RC (2008). Platelets: developmental biology, physiology, and translatable platforms for preclinical investigation and drug development. [Review]. Platelets, 19(4), 239-51.
  7. Bray PF (2007). Platelet hyperreactivity: predictive and intrinsic properties. [Review]. Hematol Oncol Clin North Am, 21(4), 633-45, v-vi.
  8. Lumsden AB, Rice TW, Chen C, Zhou W, Lin PH, Bray P, Morrisett J, Nambi V, Ballantyne C (2007). Peripheral arterial occlusive disease: magnetic resonance imaging and the role of aggressive medical management. [Review]. World J Surg, 31(4), 695-704.
  9. Vijayan KV, Bray PF (2006). Molecular mechanisms of prothrombotic risk due to genetic variations in platelet genes: Enhanced outside-in signaling through the Pro33 variant of integrin beta3. [Review]. Exp Biol Med (Maywood), 231(5), 505-13.
  10. Yee DL, Bray PF (2004). Clinical and functional consequences of platelet membrane glycoprotein polymorphisms. [Review]. Semin Thromb Hemost, 30(5), 591-600.
  11. Braunstein JB, Kershner DW, Bray P, Gerstenblith G, Schulman SP, Post WS, Blumenthal RS (2002). Interaction of hemostatic genetics with hormone therapy: new insights to explain arterial thrombosis in postmenopausal women. [Review]. Chest, 121(3), 906-20.
  12. Williams MS, Bray PF (2001). Genetics of arterial prothrombotic risk states. [Review]. Exp Biol Med (Maywood), 226(5), 409-19.
  13. Bray PF (2000). Platelet glycoprotein polymorphisms as risk factors for thrombosis. [Review]. Curr Opin Hematol, 7(5), 284-9.
  14. Bray PF (1994). Inherited diseases of platelet glycoproteins: considerations for rapid molecular characterization. [Review]. Thromb Haemost, 72(4), 492-502.

Book Chapter

  1. Edelstein LC, Nagalla S, Bray PF (2014). MicroRNAs in Platelet Production and Activation. In Lawrie C (Ed.), MicroRNAs in Medicine (pp. 101-16). Hoboken, NJ: Wiley-Blackwell.
  2. Nagalla S, Bray PF (2012). Acquired Platelet Dysfunction. In Clinical Decision Support.
  3. Bray PF, Jones CI, Soranzo N, Ouwehand WH (2012). Platelet Genomics. In Michelson A (Ed.), Platelets. San Diego: Academic Press.
  4. Nagalla S, Leal S, Bray PF (2009). Pharmacogenetics of Platelet Inhibitors. In Freedman JE, Loscalzo J (Eds.), New Therapeutic Agents in Thrombosis and Hemostasis (pp. 49-66). New York: Informa Healthcare.
  5. Afsharkarghan V, Vijayan KV, Bray PF (2006). Platelet Polymorphisms. In Michelson A (Ed.), Platelets (pp. 281-307). San Diego: Academic Press.
  6. Afsharkarghan V, Bray PF (2002). Platelet Polymorphisms. In Michelson A (Ed.), Platelets (pp. 157-80). Academic Press: Academic Press.
  7. Bray PF (1994). Glycoproteins IIb and IIIa: Insights into platelet aggregation derived from the study of Glanzmann thrombasthenia. In Spivak JS, et al (Eds.), Yearbook of Hematology (pp. 207-18). St. Louis: Mosby.

Conference Proceedings

  1. Bushnell CD, Hurn P, Colton C, Miller VM, del Zoppo G, Elkind MS, Stern B, Herrington D, Ford-Lynch G, Gorelick P, James A, Brown CM, Choi E, Bray P, Newby LK, Goldstein LB, Simpkins J (2006). Advancing the study of stroke in women: summary and recommendations for future research from an NINDS-Sponsored Multidisciplinary Working Group. Stroke, United States, 37(9), 2387-99.

Case Report

  1. Julapalli VR, Bray PF, Duchini A (2003). Elevated factor VIII and portal vein thrombosis. Dig Dis Sci, 48(12), 2369-71.
  2. Peyruchaud O, Nurden AT, Milet S, Macchi L, Pannochia A, Bray PF, Kieffer N, Bourre F (1998). R to Q amino acid substitution in the GFFKR sequence of the cytoplasmic domain of the integrin IIb subunit in a patient with a Glanzmann's thrombasthenia-like syndrome. Blood, 92(11), 4178-87.
  3. Yu DR, Miller R, Bray PF (1998). Clinical problem-solving. Through thick and thin. N Engl J Med, 338(23), 1684-7.
  4. Goldschmidt-Clermont PJ, Shear WS, Schwartzberg J, Varga CF, Bray PF (1996). Clues to the death of an Olympic champion. Lancet, 347(9018), 1833.
  5. Khouzami AN, Kickler TS, Bray PF, Callan NA, Sciscione AC, Shumway JB, Blakemore KJ (1995). Molecular genotyping of fetal platelet antigens with uncultured amniocytes. Am J Obstet Gynecol, 173(4), 1202-6.

Editorial

  1. Bray PF (2008). Sizing up platelet defects. Blood, 111, 3302-3303.

Letter

  1. Sbenghe MM, Besa E, Mahipal A, Dulau Florea A, Bray P, Caro J (2012). HHV-8-associated multicentric Castleman's disease in HIV-negative patient: a novel therapy for an orphan disease. [Letter to the editor]. Oncologist, 17(1), 145-6; author reply 147-8.
  2. Nagalla S, Bray PF (2010). Platelet RNA chips dip into thrombocytosis. [Letter to the editor]. Blood, 115(1), 2-3.
  3. Sarabia SF, Raya JL, Hoogeveen RC, Bray PF (2008). Human platelets differentially concentrate estradiol, estrone and testosterone. [Letter to the editor]. J Thromb Haemost, 6(4), 703-5.
  4. Vijayan KV, Liu Y, Souza S, Thiagarajan P, Bray PF (2006). Fibrinogen and prothrombin binding is enhanced to the Pro33 isoform of purified integrin alphaIIbbeta3. [Letter to the editor]. J Thromb Haemost, 4(4), 905-6.
  5. Cooke GE, Bray PF, Hamlington JD, Pham DM, Goldschmidt-Clermont PJ (1998). PlA2 polymorphism and efficacy of aspirin. [Letter to the editor]. Lancet, 351(9111), 1253.

Other

  1. Bray PF (2000). Platelet risk factors for arterial thrombosis. Hemost Thromb Update (17, pp. 76-85).
  2. Bray PF (1998). Coagulation Lab Handbook for Pathology and Medicine residents on the pathophysiology and interpretation of clinical coagulation testing. (pp. 1-57). Johns Hopkins University School of Medicine.

Video/Film/CD/Web/Podcast

  1. Drelich DA, Bray PF (2015). The Traditional Role of Platelets in Hemostasis, The Non-Thrombotic Role of Platelets in Health and Disease [DOI: 10.5772/60595] [Web]. InTech. Available: http://www.intechopen.com/books/the-non-thrombotic-role-of-platelets-in-health-and-disease/the-traditional-role-of-platelets-in-hemostasis.

Patent

  1. Bray PF, Holinstat M, Edelstein L (2019). Variation in the PAR4 thrombin receptor gene affects the effectiveness of PAR4 inhibitors. U.S. Patent No. [PCT filed on 10/27/2014. FIRM_DM-#14660291-v2-TJU_BRA_PAU_001_NP003252_079420_thrombosis_drug_Prov-10-17-13. Washington, D.C.:U.S. Patent and Trademark Office.
  2. Bray PF (2019). Non-Selective Protease Activated Receptor 4 Ala120Thr Isoform Antagonist. U.S. Patent No. [Provisional Patent Application Serial No. 62/242,114 filed October 15, 2015]. Washington, D.C.:U.S. Patent and Trademark Office.
  3. Bray PF, Holinstat M (2015). Methods of prevention or treatment for pathologic thrombosis or inflammation. U.S. Patent No. WO/2015/065876. Washington, D.C.:U.S. Patent and Trademark Office.
  4. Bray PF, et al (1999). Use of platelet polymorphism PlA2 to diagnose risk of thrombotic disease. U.S. Patent No. 5,955,266. Washington, D.C.:U.S. Patent and Trademark Office.

Global Impact

Site Links

  • Find an Interpreter
  • About Us
  • Academics & Research
  • Billing
  • Jobs
  • Giving
  • Maps & Directions
  • Newsroom
  • Referring Providers

Helpful Links

  • Patient Rights & Responsibilities
  • Disclaimer
  • Privacy Statement
  • DNV GL Public Information Policy Statement
  • Non-Discrimination Policy
  • Surprise Billing Rights
  • Webmaster

Contact Us

University of Utah Health

50 North Medical Drive
Salt Lake City, UT 84132

801-581-2121

  • Facebook
  • Twitter
  • Youtube

University of Utah

All clinical services and programs are part of University of Utah Health Hospitals and Clinics.

Copyright © 2022 University of Utah Health